By establishing coding and separate payment for certain digital mental health devices, this group from CMS and the FDA hopes to improve access to care.

The Centers for Medicare and Medicaid Services ("CMS") published a final notice outlining the processes and procedures for the Transitional

The U.S. Food and Drug Administration (FDA) recently issued two new guidance documents governing details of the Accelerated Approval

The Trump administration’s Centers for Medicare and Medicaid Services (CMS) has signaled that it will be revamping the process of negotiating prices for certain Medicare Part D drugs with input fro | The agency said it is "considering opportunities to bring greater transparency" and will consider stakeholder feedback on the program.

Senators grilled Robert F. Kennedy Jr. on if and how he would reform Medicaid and Medicare during his first confirmation hearing to become the next secretary of Health and Human Services.

This past year featured key developments in the prescription drug policy area, including the implementation of significant prescription drug pricing reform legislation and the election of a new administration.

CMS ultimately selected to test three models with the ... would have had Medicare pay less for drugs that receive accelerated approvals from the Food and Drug Administration (FDA). The FDA grants accelerated approvals to promising drugs to make them ...

Biden-era policies rescinded by Donald Trump could signal a significant shake-up in Medicare and Medicaid drug price reforms.

The U.S. Department of Health and Human Services has paused public communications until Feb. 1 as Trump appointees take control of health agencies.

An early move by the president has raised questions about what direction his second-term policy on drug costs will take.

Through the issuance of Inauguration Day executive orders, the Trump Administration signaled its apparent intent to tackle drug pricing reforms